Literature DB >> 20053748

Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model.

Elizabeth B Norton1, John D Clements, Thomas G Voss, Lucia Cárdenas-Freytag.   

Abstract

Prophylactic or therapeutic immunomodulation is an antigen-independent strategy that induces nonspecific immune system activation, thereby enhancing host defense to disease. In this study, we investigated the effect of prophylactic immunomodulation on the outcome of influenza virus infection using three bacterially derived immune-enhancing agents known for promoting distinct immunological profiles. BALB/c mice were treated nasally with either cholera toxin (CT), a mutant form of the CT-related Escherichia coli heat-labile enterotoxin designated LT(R192G), or CpG oligodeoxynucleotide. Mice were subsequently challenged with a lethal dose of influenza A/PR/8/34 virus 24 h after the last immunomodulation treatment and either monitored for survival or sacrificed postchallenge for viral and immunological analysis. Treatment with the three immunomodulators prevented or delayed mortality and weight loss, but only CT and LT(R192G) significantly reduced initial lung viral loads as measured by plaque assay. Analysis performed 4 days postinfection indicated that prophylactic treatments with CT, LT(R192G), or CpG resulted in significantly increased numbers of CD4 T cells, B cells, and dendritic cells and altered costimulatory marker expression in the airways of infected mice, coinciding with reduced expression of pulmonary chemokines and the appearance of inducible bronchus-associated lymphoid tissue-like structures in the lungs. Collectively, these results suggest that, despite different immunomodulatory mechanisms, CT, LT(R192G), and CpG induce an initial inflammatory process and enhance the immune response to primary influenza virus challenge while preventing potentially damaging chemokine expression. These studies provide insight into the immunological parameters and immune modulation strategies that have the potential to enhance the nonspecific host response to influenza virus infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20053748      PMCID: PMC2826051          DOI: 10.1128/JVI.01805-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  84 in total

Review 1.  The role of the antibody response in influenza virus infection.

Authors:  W Gerhard
Journal:  Curr Top Microbiol Immunol       Date:  2001       Impact factor: 4.291

2.  Prevaccine determination of the expression of costimulatory B7 molecules in activated monocytes predicts influenza vaccine responses in young and older adults.

Authors:  David van Duin; Heather G Allore; Subhasis Mohanty; Sandra Ginter; Frances K Newman; Robert B Belshe; Ruslan Medzhitov; Albert C Shaw
Journal:  J Infect Dis       Date:  2007-04-17       Impact factor: 5.226

3.  Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro.

Authors:  A Bromander; J Holmgren; N Lycke
Journal:  J Immunol       Date:  1991-05-01       Impact factor: 5.422

4.  Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection.

Authors:  Nicole Schmitz; Michael Kurrer; Martin F Bachmann; Manfred Kopf
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

5.  Intranasal immunotherapy is more effective than intradermal immunotherapy for the induction of airway allergen tolerance in Th2-sensitized mice.

Authors:  Kenji Takabayashi; Lev Libet; Dugald Chisholm; Jose Zubeldia; Anthony A Horner
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

Review 6.  Animal models in influenza vaccine testing.

Authors:  Jan Willem van der Laan; Carla Herberts; Robert Lambkin-Williams; Alison Boyers; Alexander J Mann; John Oxford
Journal:  Expert Rev Vaccines       Date:  2008-08       Impact factor: 5.217

7.  Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge.

Authors:  Hiromasa Hamada; Maria de la Luz Garcia-Hernandez; Joyce B Reome; Sara K Misra; Tara M Strutt; Kai K McKinstry; Andrea M Cooper; Susan L Swain; Richard W Dutton
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

8.  Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine.

Authors:  Xiuhua Lu; J D Clements; Jacqueline M Katz
Journal:  Vaccine       Date:  2002-01-15       Impact factor: 3.641

9.  Modulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G).

Authors:  Marcel Maier; Timothy J Seabrook; Cynthia A Lemere
Journal:  Vaccine       Date:  2005-10-25       Impact factor: 3.641

10.  Intranasal delivery of cholera toxin induces th17-dominated T-cell response to bystander antigens.

Authors:  Jee-Boong Lee; Ji-Eun Jang; Man Ki Song; Jun Chang
Journal:  PLoS One       Date:  2009-04-10       Impact factor: 3.240

View more
  24 in total

1.  Mapping the pulmonary environment of animals protected from virulent H1N1 influenza infection using the TLR-2 agonist Pam₂Cys.

Authors:  Edin J Mifsud; Amabel C L Tan; Patrick C Reading; David C Jackson
Journal:  Immunol Cell Biol       Date:  2015-08-14       Impact factor: 5.126

2.  A critical role of IL-17 in modulating the B-cell response during H5N1 influenza virus infection.

Authors:  Xiaohui Wang; Chris C S Chan; Min Yang; Jun Deng; Vincent K M Poon; Virtual H C Leung; King-Hung Ko; Jie Zhou; Kwok Yung Yuen; Bo-Jian Zheng; Liwei Lu
Journal:  Cell Mol Immunol       Date:  2011-09-26       Impact factor: 11.530

3.  Direct IL-6 Signals Maximize Protective Secondary CD4 T Cell Responses against Influenza.

Authors:  Tara M Strutt; Karl Kai McKinstry; Yi Kuang; Caroline M Finn; Ji Hae Hwang; Kunal Dhume; Stewart Sell; Susan L Swain
Journal:  J Immunol       Date:  2016-09-19       Impact factor: 5.422

4.  Reducing the impact of influenza-associated secondary pneumococcal infections.

Authors:  Edin J Mifsud; Amabel C Tan; Kirsty R Short; Lorena E Brown; Brendon Y Chua; David C Jackson
Journal:  Immunol Cell Biol       Date:  2015-07-21       Impact factor: 5.126

5.  Glucan supplementation enhances the immune response against an influenza challenge in mice.

Authors:  Vaclav Vetvicka; Jana Vetvickova
Journal:  Ann Transl Med       Date:  2015-02

6.  Nonhuman primate infants have an impaired respiratory but not systemic IgG antibody response following influenza virus infection.

Authors:  Beth C Holbrook; Sarah L Hayward; Lance K Blevins; Nancy Kock; Tyler Aycock; Griffith D Parks; Martha A Alexander-Miller
Journal:  Virology       Date:  2014-12-24       Impact factor: 3.616

Review 7.  Vaccines against respiratory viral pathogens for use in neonates: opportunities and challenges.

Authors:  Martha A Alexander-Miller
Journal:  J Immunol       Date:  2014-12-01       Impact factor: 5.422

Review 8.  Recent progress concerning CpG DNA and its use as a vaccine adjuvant.

Authors:  Hidekazu Shirota; Dennis M Klinman
Journal:  Expert Rev Vaccines       Date:  2013-11-26       Impact factor: 5.217

9.  Adenovirus-vectored drug-vaccine duo as a rapid-response tool for conferring seamless protection against influenza.

Authors:  Jianfeng Zhang; E Bart Tarbet; Tsungwei Feng; Zhongkai Shi; Kent R Van Kampen; De-chu C Tang
Journal:  PLoS One       Date:  2011-07-27       Impact factor: 3.240

10.  Phytol-derived novel isoprenoid immunostimulants.

Authors:  Roshni Roy Chowdhury; Swapan K Ghosh
Journal:  Front Immunol       Date:  2012-03-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.